Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DHEA for Mid-Life Mood Disorders
NCT00001487Phase 2Completed
- Sponsor
- National Institute of Mental Health
- Start
- Jun 1995
- Modality
- Allosteric Modulators
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of dehydroepiandrosterone in major depressive disorder (MDD), Minor depressive disorder and persistent depressive disorder (PDD) (2 arms), sponsored by National Institute of Mental Health. Primary endpoints: 17-Item Hamilton Depression Rating Scale at 6 weeks and Center for Epidemiologic Studies Depression Scale at 6 weeks. Started Jun 1995; status: completed.
02
Drugs
dehydroepiandrosterone
03
Conditions
major depressive disorder (MDD)Minor depressive disorderpersistent depressive disorder (PDD)
Beyond the preview
Go deeper on NCT00001487.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00001487.